Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Bortezomib treatment for multiple myeloma can cause cardiovascular adverse events (CVAEs), with severe events occurring in about 15% of Korean patients. Close monitoring for CVAE symptoms is crucial, especially for those with identified risk factors.
Area Of Science
- Oncology
- Cardiology
- Pharmacology
Background
- Cardiotoxicity of proteasome inhibitors, particularly bortezomib, remains controversial.
- Real-world data on bortezomib-associated cardiovascular adverse events (CVAEs) are limited.
- This study investigates CVAEs in multiple myeloma patients treated with bortezomib.
Purpose Of The Study
- To determine the incidence of CVAEs in patients with multiple myeloma receiving bortezomib.
- To identify risk factors associated with bortezomib-induced CVAEs.
- To evaluate the impact of CVAEs on survival outcomes.
Main Methods
- A cross-sectional study of 395 multiple myeloma patients treated with bortezomib in South Korea.
- CVAEs (hypertension, arrhythmia, heart failure, etc.) were identified through clinical data and monitoring.
- Patients were observed for 6 months to 2 years post-treatment initiation.
Main Results
- 20.8% of patients experienced any-grade CVAEs; 14.7% had severe CVAEs.
- New-onset or worsened hypertension was the most common CVAE, with a median onset of 101.5 days.
- Risk factors for CVAEs included low BMI (<18.5), specific myeloma subtypes (light chain, IgD), and history of stroke or hypertension.
Conclusions
- Severe CVAEs affect approximately 15% of Korean patients undergoing bortezomib therapy.
- Identifying patients with risk factors is essential for proactive CVAE monitoring.
- Close surveillance for CVAE symptoms during bortezomib treatment is recommended.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...